

Alessandro Volpe

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4640964/alessandro-volpe-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33
papers

654
citations

14
h-index

25
g-index

34
ext. papers

745
ext. citations

3.5
avg, IF

2.85
L-index

#	Paper	IF	Citations
33	Practical approach to vasculitides in adults: an overview of clinical conditions that can mimic vasculitides closely 2020 , 2, 3-13		1
32	Vitamin D and autoimmune rheumatic diseases. <i>Clinical Rheumatology</i> , 2011 , 30, 443-4	3.9	3
31	Very low levels of vitamin D in systemic sclerosis patients. <i>Clinical Rheumatology</i> , 2010 , 29, 1419-25	3.9	71
30	A study on thrombophilic factors in Italian Behcet's patients. <i>Joint Bone Spine</i> , 2010 , 77, 330-4	2.9	24
29	Étude des facteurs de thrombophilie chez les patients italiens atteints de maladie de Behçet. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2010 , 77, 357-361	0.1	0
28	Ultrasound evaluation of ulnar neuropathy at the elbow: correlation with electrophysiological studies. <i>Rheumatology</i> , 2009 , 48, 1098-101	3.9	92
27	Anti-TNFalpha blockers, autoantibodies and autoimmune diseases. <i>Joint Bone Spine</i> , 2009 , 76, 333-42	2.9	27
26	Familial hypocalciuric hypercalcemia revealed by chondrocalcinosis. <i>Joint Bone Spine</i> , 2009 , 76, 708-10	2.9	35
25	Cyclophosphamide treatment improves microvessel damage in systemic sclerosis. <i>Clinical Rheumatology</i> , 2009 , 28, 391-5	3.9	34
24	A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost. <i>Clinical Rheumatology</i> , 2009 , 28, 807-13	3.9	30
23	Clinical associations of anti-CENP-B and anti-Scl70 antibody levels measured by multiplexed fluorescent microsphere immunoassay in systemic sclerosis. <i>Rheumatology International</i> , 2009 , 29, 1073-9	3.6	10
22	Anti-TNFalpha, autoanticorps et maladies auto-immunes. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2009 , 76, 616-625	0.1	
21	Dramatic progression of skin involvement in systemic sclerosis after the appearance of anti-Scl70 antibody: a case report. <i>Rheumatology International</i> , 2008 , 28, 385-6	3.6	1
20	Iloprost infusion does not reduce oxidative stress in systemic sclerosis. <i>Rheumatology International</i> , 2008 , 28, 335-7	3.6	5
19	Celiac disease in a rheumatology unit: a case study. <i>Rheumatology International</i> , 2008 , 28, 547-51	3.6	2
18	Hydroxychloroquine-induced DRESS syndrome. <i>Clinical Rheumatology</i> , 2008 , 27, 537-9	3.9	27
17	B-flow ultrasound in a case of giant cell arteritis. <i>Clinical Rheumatology</i> , 2007 , 26, 1955-7	3.9	5

16	Coexistence of systemic sclerosis with other autoimmune diseases. <i>Rheumatology International</i> , 2007 , 27, 407-10	3.6	36
15	Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results. <i>Rheumatology International</i> , 2007 , 27, 649-54	3.6	15
14	Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature. <i>Clinical Rheumatology</i> , 2007 , 26, 1795-6	3.9	8
13	Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis. <i>Clinical Biochemistry</i> , 2007 , 40, 837-42	3.5	12
12	Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity. <i>Rheumatology International</i> , 2006 , 26, 209-14	3.6	60
11	Psoriasis onset during infliximab treatment: description of two cases. <i>Rheumatology International</i> , 2006 , 26, 1158-60	3.6	6
10	Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results. <i>Rheumatology International</i> , 2006 , 27, 203-5	3.6	14
9	Evaluation of cardiac laboratory markers in patients with systemic sclerosis. <i>Clinical Biochemistry</i> , 2006 , 39, 913-7	3.5	44
8	Evaluation of finger skin temperature in scleroderma patients cyclically treated with iloprost. <i>Joint Bone Spine</i> , 2006 , 73, 57-61	2.9	4
7	Lipoprotein[a] and the lipid profile in patients with systemic sclerosis. <i>Clinica Chimica Acta</i> , 2006 , 364, 345-8	6.2	30
6	Thyroid status in patients with systemic sclerosis. <i>Journal of Clinical Rheumatology</i> , 2006 , 12, 322-4	1.1	3
5	Plasma D-dimer concentration in patients with systemic sclerosis. <i>Thrombosis Journal</i> , 2006 , 4, 2	5.6	4
4	Évaluation de la température cutanée des patients atteints de sclérodermie traités périodiquement par iloprost. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2006 , 73, 53-57	0.1	1
3	Low levels of activated factor VII in systemic sclerosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2006 , 22, 133-8	5.1	
2	Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions. <i>Rheumatology International</i> , 2005 , 25, 250-4	3.6	4
1	Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. <i>Rheumatology International</i> , 2005 , 26, 58-62	3.6	45